Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

Pfizer and BioNTech get positive CHMP opinion for updated bivalent BA.4/BA.5-adapted COVID-19 vaccine booster 

By Brian Buntz | September 12, 2022

Pfizer-BioNTechPfizer (NYSE: PFE) and its partner BioNTech (Nasdaq:BNTX) could potentially win authorization to market a 30-µg booster dose of their omicron BA.4/BA.5 bivalent-adapted COVID-19 vaccine after the Committee for Medicinal Products for Human Use (CHMP) backed the vaccine for individuals 12 and older.

The European Commission will likely make a final decision on the updated vaccine soon.

The updated vaccine has won emergency use authorization in the U.S. for use as a booster.

The new vaccine contains 15-µg of mRNA encoding the spike protein of the original form of SARS-CoV-2 and 15-µg of mRNA encoding the spike protein of the omicron BA.4/BA.5 sublineages.

Earlier this month, Pfizer and BioNatech announced they received a positive CHMP opinion for an omicron BA.1-adapted bivalent COVID-19 vaccine booster.

“Due to our multifaceted approach helping to address emerging variants and subvariants of concern, public health authorities in the EU will have our bivalent booster options, pending authorization, to facilitate flexible vaccination strategies for maximal coverage across the region,” said Pfizer CEO Albert Bourla in a news release.

CHMP’s endorsement of the BA.4/BA.5 bivalent-adapted COVID-19 vaccine was based on data from Pfizer’s and BioNTech’s omicron BA.1-adapted bivalent vaccine in addition to pre-clinical and manufacturing data from the omicron BA.4/BA.5-adapted bivalent vaccine.

The BA.4/Ba.5-adapted vaccine fared well in pre-clinical studies against the BA.1, BA.2, BA.4 and BA.5 omicron sublineages.

Many countries, including the U.S., UK, Switzerland and Australia, have also backed updated COVID-19 vaccines.

PFE shares edged up 0.52% to $48.09 in mid-day trading, while BNTX shares were down 1.33% to $148.90.

In late August, Moderna (Nasdaq:MRNA) announced that it was suing Pfizer (NYSE:PFE) and its partner BioNTech (Nasdaq:BNTX) over patent infringement in U.S. and German courts.

Moderna’s vaccine, like the Pfizer-BioNtech vaccine, uses an mRNA backbone. Pfizer disputes that its vaccine jointly developed with BioNTech was based on Moderna’s.

BA.4 and BA.5 continue to drive the majority of SARS-CoV-2 infections internationally.

 

About The Author

Brian Buntz

The pharma and biotech editor of WTWH Media, Brian is a veteran journalist with more than 15 years of experience covering an array of life science topics, including clinical trials, drug discovery and development and medical devices. Before coming to WTWH, he served as content director focused on connected devices at Informa. In addition, Brian covered the medical device sector for 10 years at UBM. At Qmed, he overhauled the brand’s news coverage and helped to grow the site’s traffic volume dramatically. He had previously held managing editor roles on two of the company’s medical device technology publications. Connect with him on LinkedIn or email at bbuntz@wtwhmedia.com.

Tell Us What You Think! Cancel reply

Related Articles Read More >

institut pasteur dakar IPD African Union vaccine investment
African Union vaccine initiative receives $45M
Sen-Jam Pharma, KVK-Tech partnering for manufacturing and formulation for anti-inflammatory injectables
This image shows the Moderna logo.
Moderna resizes its manufacturing footprint for a post-pandemic era
This is the logo of Pfizer.
Pfizer to close Durham and Morrisville, North Carolina facilities amid major restructuring effort
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE